BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35158787)

  • 1. Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi.
    Nassi L; De Sanctis V; Loseto G; Gerardi C; Allocati E; Ciavarella S; Minoia C; Guarini A; Bari A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.
    Oliva S; Puzzovivo A; Gerardi C; Allocati E; De Sanctis V; Minoia C; Skrypets T; Guarini A; Gini G
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.
    Di Molfetta S; Daniele A; Gerardi C; Allocati E; Minoia C; Loseto G; Giorgino F; Guarini A; De Sanctis V
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi.
    Minoia C; Gerardi C; Allocati E; Daniele A; De Sanctis V; Bari A; Guarini A
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.
    Franceschetti S; Annunziata MA; Agostinelli G; Gerardi C; Allocati E; Minoia C; Guarini A
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews.
    Gerardi C; Allocati E; Minoia C; Guarini A; Banzi R
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34198635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Male and Female Fertility: Prevention and Monitoring Hodgkin' Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors. A Systematic Review by the Fondazione Italiana Linfomi.
    Viviani S; Caccavari V; Gerardi C; Ramadan S; Allocati E; Minoia C; Guarini A; Di Russo A
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
    Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
    Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality.
    Parsons MW; Rock C; Chipman JJ; Shah HR; Hu B; Stephens DM; Tao R; Tward JD; Gaffney DK
    Cancer Med; 2023 Feb; 12(3):2624-2636. PubMed ID: 36812123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.
    Filippi AR; Meregalli S; DI Russo A; Levis M; Ciammella P; Buglione M; Guerini AE; De Marco G; De Sanctis V; Vagge S; Ricardi U; Simontacchi G;
    Radiat Oncol; 2020 Mar; 15(1):62. PubMed ID: 32164700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Santi RM; Ceccarelli M; Bernocco E; Monagheddu C; Evangelista A; Valeri F; Monaco F; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Visco C; Calabrese M; Limberti G; Levis A; Contino L; Ciccone G; Ladetto M
    Thromb Haemost; 2017 Apr; ():. PubMed ID: 28447710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
    Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
    Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
    Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
    [No Abstract]   [Full Text] [Related]  

  • 15. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
    Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
    Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
    Jiang S; Zhen H; Jiang H
    Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
    Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
    Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.
    Bataillard EJ; Cheah CY; Maurer MJ; Khurana A; Eyre TA; El-Galaly TC
    Blood Adv; 2021 May; 5(9):2426-2437. PubMed ID: 33961018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.